Table 1.
Demographic Characteristics of the Patients
| Characteristics | ALL (n = 88) |
|---|---|
| Sex (male/female), n | 75/13 |
| Age, median [IQR], (years) | 53.0, (46.3–62.0) |
| ECOG PS (0/1), n | 86/2 |
| mALBI (1/2a/2b/3), n | 18/23/43/4 |
| Child-Pugh classification (A/B), n | 77/11 |
| Aetiology of HCC (hepatitis B/non-B, non-C), n | 81/7 |
| Platelet count, median [IQR], (×109/L) | 165 (102.3–237.5) |
| Neutrophils, median [IQR], (×109/L) | 3.10 (2.30–4.47) |
| Lymphocytes, median [IQR], (×109/L) | 1.04 (0.80–1.49) |
| Albumin, median [IQR], (g/L) | 35.2 (32.7–39.0) |
| Total bilirubin, median [IQR], (µmol/L) | 17.4 (10.9–26.7) |
| Alanine aminotransferase, median [IQR], (U/L) | 39.7 (22.5–51) |
| Aspartate aminotransferase, median [IQR], (U/L) | 53.9 (37.3–92.9) |
| γ-glutamyl transpeptidase, median [IQR], (U/L) | 140.5 (67.3–277.5) |
| Alkaline phosphatase, median [IQR], (U/L) | 143.1 (103.0–221.6) |
| AFP (≥400/<400), n (ng/mL) | 49/39 |
| Tumor Number (1/2/3/≥4), n | 23/5/1/59 |
| Maximum diameter of tumor, median [IQR], (cm) | 9.90, (6.64–12.44) |
| Macrovascular invasion (yes/no), n | 45/43 |
| PVTT (0/Vp2/Vp3/Vp4), n | 45/6/22/15 |
| HVTT (0/Vv2/Vv3), n | 84/2/2 |
| Extrahepatic Spread (yes/no), n | 20/68 |
| BCLC Stage (A/B/C), n | 6/25/57 |
| NLR, median, [IQR] | 3.46, (1.96–4.40) |
| Follow-up duration, median [IQR], (months) | 11.4 (7.0–15.7) |
| HAIC regimen (FOLFOX/RALOX), n | 74/14 |
Abbreviations: IQR, interquartile range; AFP, alpha-fetoprotein; ECOG PS, Eastern Cooperative Oncology Group performance status; mALBI, modified albumin-bilirubin; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; NLR, neutrophil-to-lymphocyte ratio; HAIC, hepatic arterial infusion chemotherapy; FOLFOX, 5-fluorouracil, oxaliplatin, and leucovorin; RALOX, raltitrexed, and oxaliplatin; PVTT, portal vein tumor thrombosis; HVTT, hepatic vein tumor thrombus.